Current Report Filing (8-k)
July 09 2020 - 5:01PM
Edgar (US Regulatory)
0001267565
false
0001267565
2020-07-08
2020-07-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 8, 2020
COLLEGIUM PHARMACEUTICAL, INC.
(Exact Name of Registrant as Specified
in its Charter)
Virginia
|
|
001-37372
|
|
03-0416362
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
|
(Commission File Number)
|
|
(IRS Employer Identification
No.)
|
100 Technology Center Drive
Suite 300
Stoughton, MA 02072
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (781) 713-3699
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per share
|
COLL
|
The NASDAQ Global Select Market
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On July 8, 2020, David Hirsch, M.D., Ph.D. notified the Board
of Directors (the “Board”) of Collegium Pharmaceutical, Inc. (the “Company”) that he would resign from
the Board as a Class I director and all committees thereof, effective July 9, 2020, to devote his full time efforts to his other
commitments; his resignation was not the result of any disagreement with the Company on any matter relating to its operations,
policies or practices. With best wishes, the Company thanks Dr. Hirsch for his dedicated service and valuable contribution as a
member of the Board since February 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 9, 2020
|
Collegium Pharmaceutical, Inc.
|
|
|
|
|
By:
|
/s/ Paul Brannelly
|
|
|
Name: Paul Brannelly
|
|
|
Title: Executive Vice President and Chief Financial Officer
|
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Apr 2023 to Apr 2024